Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.42 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1833867 | 0.84 | HCAR2 (0.50) | HCAR2ALDH1A1ALOX15RECQLHSD17B10 | |
| Fumaric Acid SCHEMBL1833865 | 0.84 | HCAR2 (0.50) | HCAR2ALDH1A1ALOX15RECQLHSD17B10 | |
| Acetic Acid SCHEMBL8439700 | 0.84 | HPGD (0.39) | ALDH1A1TSHRKDM4ETDP1HPGD | |
| Maleic Acid SCHEMBL31607494 | 0.81 | TSHR (0.53) | HCAR2HRH1ALDH1A1ALOX15RECQL | |
| Maleic Acid SCHEMBL4493043 | 0.79 | HCAR2 (0.45) | HCAR2ALDH1A1ALOX15RECQLHSD17B10 | |
| SCHEMBL14980473 | 0.79 | ALDH1A1 (0.51) | HCAR2ALDH1A1HPGDTAAR1LMNA | |
| SCHEMBL22912842 | 0.79 | HCAR2 (0.62) | HCAR2HRH1ALDH1A1ALOX15RECQL | |
| Methoxyacetic Acid SCHEMBL28141140 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHRKDM4ETDP1HPGD | |
| SCHEMBL40164 | 0.78 | — | — | |
| SCHEMBL15453344 | 0.77 | HCAR2 (0.41) | HCAR2ALDH1A1TSHRTP53EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | HRH1 2410/4885KMT2A 2877/4885HCAR2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.